多塞平与马来酸曲美布汀单用或联用治疗肠易激综合征的临床观察

将193例肠易激综合征患者随机分为3组：多塞平联合马来酸曲美布汀组73例；多塞平组56例，单独给予多塞平口服；马来酸曲美布汀组64例，单独给予马来酸曲美布汀口服。多塞平12．5～25．0mg每日3次餐前口服，马来酸曲美布汀200mg每日3次餐前口服，疗程均为4周。结果示3组总有效率分别为95．9％、83．9％和81．3％，多塞平加马来酸曲美布汀组疗效明显优于单用多塞平和马来酸曲美布汀组（均P〈0．01），尤其对腹泻型肠易激综合征疗效最佳；对神经精神症状的改善率分别为87．0％、79．0％和71．6％，以联合用药组疗效为佳（均P〈0．01）。提示多塞平、马来酸曲美布汀单用或联用治疗肠易激综合征均有效，联合用药治疗可明显提高疗效。

A clinical observation of single doxepin or trimebutine mealate and combination of them in the treatment of irritable bowel syndrome

193 patients with irritable bowel syndrome (IBS) were divided into 3 groups stochastically:73 cases were treated with both trimebutine malate and doxepin. 56 cases were only treated with doxepin, and this group was given doxepin to take orally. The other 64 cases were only treated with trimebutine malate. This group were given trimebutine malate to take orally. Doxepin was given 12.5-25.0 mg tid po, and trimebutine malate was given 200 mg tid po. This is for a course of 4-week-therapy. The rates of the total response of the 3 groups were 95.9%, 83.9% and 81.3% respaefively. The effect of the combination of the 2 drugs is much higher than the other two (P<0.01), and especially it has the highest effect on diarrhea type IBS. The rates of the improvement of nervos and mental symptoms were 87.0%, 79.0% and 71.6% respectively. The effect of combination use is the highest. It suggests that both the single use and combination use of doxepin and trimebutine malate has the effect on the treatment of IBS, but the combination use can improve the effect obviously.